Source: Annual Congress 2010 - Influenza A (H1N1) and other viral infections: therapeutic aspects
Disease area: Respiratory infections

Abstract

Background: Few studies have addressed the etiology and clinical outcomes of CAP treated in an ambulatory setting.
Methods:
Blood and sputum culture, throat swab culture for M. pneumoniae, urine for rapid antigen testing of S. pneumoniae and L.pneumoniae were obtained. Presence of M. pneumoniae and 14 kinds of respiratory virus DNA or RNA from sputum were determined. Treatment outcomes were measured by speed of resolution of morbidities.
Results: 197 patients were enrolled in the study, with the median age of 32.5 years, and 95.2% of Fine classes I to III. An etiological diagnosis was made in 51.8%. The most common pathogens were M. pneumoniae (29.4%) followed by Influenza virus A, parainfluenza virus, adenovirus, human metapneumovirus (9.6%) and S. pneumoniae (4.1%). Patients with different causative pathogens had different clinical features: M. pneumoniae infections, younger and less likely to present with purulent sputum; bacterial infections, more likely to have comorbidities and higher leukocyte count; viral infections, more likely to have poorly defined nodules. Among patients infected with M. pneumoniae, those treated with quinolones had shorter duration of fever (p<0.05).Conclusions: M. pneumoniae and respiratory viruses were the most frequent pathogens found in ambulatory adult CAP patients; quinilones were better than b-lactams, macrolides in resolution of fever of M. pneumoniae pneumonia.

Rating:

Share or cite this content

Citations should be made in the following way:
B. Cao, L. L. Ren, F. Zhao, C. Wang (Beijing, China). Viral and M. pneumoniae community acquired pneumonia and novel clinical outcome evaluation in ambulatory adult patients. Eur Respir J 2010; 36: Suppl. 54, 2979

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of clinical efficiency of thiotriazolin in complex treatment of patients with community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006 The general evaluation of elderly patients with community acquired pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 412s Year: 2004 The general evaluation of community acquired pneumonia patients treated in our clinic Source: Eur Respir J 2004; 24: Suppl. 48, 414s Year: 2004 Clinical presentation and evolution of community acquired pneumonia in older patients Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Fusing ICU clinical care and clinical research in severe community acquired pneumonia Source: International Congress 2016 – PG16 Infection control in epidemics: strengthening the evidence base for healthcare workers and the public Year: 2016 Severe community acquired pneumonia: clinical and aetiological evaluation Source: Eur Respir J 2007; 30: Suppl. 51, 673s Year: 2007 Therapeutic regimens in community acquired pneumonia (CAP): association with patients characteristics and outcomes Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 Clinical failure in hospitalized patients with community acquired pneumonia (CAP): Preliminary results from the FAILCAP study Source: Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia Year: 2011 Progress of quality indicator rates regarding treatment of patients hospitalized in Germany due to community acquired pneumonia (CAP) Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 Epidemiology, antimicrobial resistance and clinical outcomes in nursing home associated pneumonia compared to community acquired pneumonia Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Effect of a quality improvement plan on the outcome of patients with community acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 545s Year: 2003 An RDW-based clinical model predicts long-term survival in patients hospitalized with community acquired pneumonia (CAP): a derivation and validation multicentric study Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Clinical features associated with mortality in patients with community acquired pneumonia requiring hospitalisation Source: Eur Respir J 2004; 24: Suppl. 48, 414s Year: 2004 A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia Source: Eur Respir J 2001; 18: 362-368 Year: 2001 Significance of comorbidity in elderly patients with community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 3s Year: 2006 Outcome of community aquired pneumonia in elderly patients Source: Eur Respir J 2006; 28: Suppl. 50, 530s Year: 2006 Contribution of clinical pulmonary infection score in the diagnosis of hospital acquired pneumonia Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 Clinical management of patients newly diagnosed with COPD through targeted case finding and routine care: a longitudinal analysis of the TargetCOPD trial Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Diagnosis and management of community acquired pneumonia in adults Source: Virtual Congress 2020 – Clinical grand round: revisiting current guidelines Year: 2020 Features of community acquired pneumonia in patients hospitalized in the institute for pulmonary diseases over a five-year period Source: Eur Respir J 2006; 28: Suppl. 50, 165s Year: 2006